Sarepta Therapeutics Inc

SRPT

Equity

ISIN US8036071004 / Valor 19028527

NASDAQ (2024-09-17)

USD 125.69+1.09%

Sarepta Therapeutics Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Sarepta Therapeutics Inc. is a global biotechnology firm focused on developing precision genetic medicines for rare diseases. The company leverages cutting-edge science in gene therapy, RNA technologies, and gene editing to address conditions that have limited treatment options. Sarepta's approach is characterized by its urgency to develop therapies that can significantly alter the course of diseases by targeting their genetic roots. With a portfolio that spans several advanced platforms, the company aims to provide transformative treatments in areas of high unmet medical need. Sarepta's commitment to innovation in genetic medicine positions it as a key player in the biotech industry, striving to offer hope and tangible solutions to patients facing life-altering diagnoses.

Summarized from source with an LLMView SourceSector: Technology

Revenue Growth

Sarepta Therapeutics Inc. reported total revenues of $362.9 million for the second quarter of 2024, marking a 39% increase compared to $261.2 million in the same quarter of the previous year. This significant growth was primarily driven by the successful product launch of ELEVIDYS.

Net Income

For the second quarter of 2024, Sarepta Therapeutics Inc. achieved a GAAP net income of $6.5 million, a substantial improvement from a net loss of $23.9 million in the same period of 2023. On a non-GAAP basis, the company reported a net income of $46.7 million, compared to a net loss of $89.9 million in the prior year’s quarter.

Product Performance

ELEVIDYS, Sarepta Therapeutics Inc.'s gene therapy product, generated $121.7 million in net product revenue for the second quarter of 2024. This strong performance contributed significantly to the overall revenue growth and positions the company for further expansion in the latter half of the year.

Future Revenue Guidance

Sarepta Therapeutics Inc. has provided net product revenue guidance for 2025, projecting revenues to be in the range of $2.9 billion to $3.1 billion. This optimistic outlook is based on early launch signals and the continuing performance of their PMO products.

Operating Income

For the second quarter of 2024, Sarepta Therapeutics Inc. reported a GAAP operating loss of $0.7 million, a significant improvement from a loss of $133.5 million in the same quarter of 2023. On a non-GAAP basis, the company achieved an operating income of $57.9 million, compared to a loss of $75.5 million in the prior year’s quarter.

Summarized from source with an LLMView Source

Key figures

6.16%1Y

45.5%3Y

48.1%5Y

Performance

68.1%1Y

56.9%3Y

63.8%5Y

Volatility